Mast Cell Activation Dynamics
Mast cell activation syndrome (MCAS) is increasingly recognized as a comorbidity of ME/CFS, with prevalence estimates of 15–30% in ME/CFS cohorts (Frioni et al. 2024). Mast cells reside in tissues (skin, gut mucosa, perivascular spaces) and release a broad spectrum of mediators upon activation, affecting vascular tone, gut permeability, inflammation, and pain signaling. No prior ME/CFS model has formalized mast cell dynamics, despite their contribution to multiple symptom domains.
1 Mast Cell Degranulation Model
The model tracks resting mast cells (\(\text{MC}_r\)), primed mast cells (\(\text{MC}_p\)), and degranulated mast cells (\(\text{MC}_d\)), with degranulation releasing histamine (\([\text{His}]\)), tryptase, and prostaglandin D₂ (PGD₂):
\[ \begin{aligned} \frac{d \text{MC}_r}{d t} &= s_{\text{MC}} - k_{\text{prime}}(\mathbf{S}_{\text{MC}}) \cdot \text{MC}_r + k_{\text{restab}} \cdot \text{MC}_d - d_{\text{MC}} \cdot \text{MC}_r \\ \frac{d \text{MC}_p}{d t} &= k_{\text{prime}}(\mathbf{S}_{\text{MC}}) \cdot \text{MC}_r - k_{\text{degran}}(\mathbf{T}_{\text{MC}}) \cdot \text{MC}_p - k_{\text{deact}} \cdot \text{MC}_p \\ \frac{d \text{MC}_d}{d t} &= k_{\text{degran}}(\mathbf{T}_{\text{MC}}) \cdot \text{MC}_p - k_{\text{restab}} \cdot \text{MC}_d \end{aligned} \tag{1}\]
where \(s_{\text{MC}}\) is the tissue replenishment rate, \(k_{\text{prime}}(\mathbf{S}_{\text{MC}})\) is the priming rate driven by signals \(\mathbf{S}_{\text{MC}}\) (IgE, complement C3a/C5a, SCF), \(k_{\text{degran}}(\mathbf{T}_{\text{MC}})\) is the degranulation trigger rate driven by stimuli \(\mathbf{T}_{\text{MC}}\) (mechanical stress, temperature, exercise, neuropeptides), and \(k_{\text{restab}}\) is the restabilization rate.
2 Mediator Release and Downstream Effects
Degranulation releases mediators with distinct kinetics and targets:
\[ \begin{aligned} \frac{d [\text{His}]}{d t} &= \sigma_{\text{His}} \cdot k_{\text{degran}} \cdot \text{MC}_p - v_{\text{DAO}} \cdot \frac{[\text{His}]}{K_{\text{DAO}} + [\text{His}]} - v_{\text{HNMT}} \cdot \frac{[\text{His}]}{K_{\text{HNMT}} + [\text{His}]} \\ \frac{d [\text{PGD}_2]}{d t} &= \sigma_{\text{PG}} \cdot k_{\text{degran}} \cdot \text{MC}_p - \delta_{\text{PG}} [\text{PGD}_2] \end{aligned} \tag{2}\]
where DAO (diamine oxidase) and HNMT (histamine N-methyltransferase) are the two histamine degradation enzymes. Histamine acts on four receptor subtypes with distinct tissue effects: H1 (vasodilation, bronchoconstriction, pruritus), H2 (gastric acid, cardiac inotropy), H3 (CNS neurotransmission), and H4 (immune cell chemotaxis). The model couples histamine to existing subsystems:
- Autonomic coupling: Histamine-mediated vasodilation reduces systemic vascular resistance, entering the orthostatic model (orthostatic) as an additional MAP perturbation: \(\Delta \text{MAP}_{\text{His}} = -\alpha_{\text{H1}} \cdot [\text{His}] \\/ (K_{\text{H1}} + [\text{His}])\)
- Gut coupling: Histamine increases intestinal permeability, amplifying LPS translocation (gut immune) by a factor \((1 + \alpha_{\text{His,gut}} \cdot [\text{His}])\)
- Immune coupling: Mast cell TNF-\(\alpha\) and IL-6 release enter the cytokine network (cytokine general)
- Neurological coupling: Histamine crosses the BBB and modulates sleep–wake regulation (H3 receptor antagonism promotes wakefulness) and pain sensitization
This multi-system coupling reveals a result accessible only through the integrated mathematical model: mast cell activation simultaneously worsens orthostatic intolerance (vasodilation), gut permeability (barrier disruption), inflammation (cytokine release), and neurological symptoms (pain sensitization, sleep disruption). Verbal reasoning lists these effects independently; the model quantifies their mutual amplification. The energy–immune coupling means that the inflammatory cost of a mast cell flare further depletes ATP, reducing the energy available for DAO-mediated histamine clearance—creating a positive feedback loop between mast cell activation and energy deficit. The loop gain determines whether a mast cell flare is self-limiting (healthy) or self-amplifying (MCAS phenotype), and the model predicts that patients with \(\alpha_{\text{CI}} < 0.7\) are at substantially higher risk of self-amplifying degranulation cascades.
3 Pharmacological Predictions
The mast cell model predicts dose–response relationships for stabilizers and antihistamines:
- H1 antihistamines (cetirizine, fexofenadine): reduce \(\alpha_{\text{H1}}\), attenuating vasodilation and pruritus but not preventing degranulation. Model predicts partial symptom relief with persistence of inflammatory and gut effects—consistent with clinical experience of incomplete response to antihistamines alone.
- H2 antihistamines (famotidine): combined H1+H2 blockade is predicted to be synergistic for orthostatic symptoms because H2 receptors mediate cardiac effects that compound H1-mediated vasodilation.
- Mast cell stabilizers (cromolyn, ketotifen): reduce \(k_{\text{degran}}\) directly, preventing mediator release. The model predicts these should have broader efficacy than receptor antagonists because they prevent all downstream effects simultaneously. Ketotifen (dual stabilizer/H1 antagonist) is predicted to outperform either mechanism alone.
- DAO supplementation: increases \(v_{\text{DAO}}\), accelerating histamine clearance. The model predicts greatest benefit in patients with low endogenous DAO activity—identifiable by elevated plasma histamine-to-DAO ratio.